Hepatitis C Virus
Conditions
Keywords
Hepatitis C Virus, Observational, Brazil
Brief summary
The purpose of the study is to describe: 1) the clinical profile, past and current management of participants with hepatitis C in Brazil reference centers; 2) the current situation about demographics characteristics, liver disease progression and clinical outcomes in Brazilian Hepatitis C virus (HCV) participants naive, in treatment and previously exposed to antiviral treatment without sustained virological response (SVR).
Detailed description
This is an observational, non-interventional, cross-sectional, multicenter study to describe demographic characteristics, treatment performed and clinical outcomes of Brazilian participants with HCV chronic infection in about 12 Brazilian reference centers. It will expect that approximately 2000 participants will be enrolled in the study. Analysis set will consist of participants with HCV chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype. The study related data will be collected from the medical records in the predesigned electronic Case Report Form (eCRF).
Interventions
None listed
Sponsors
Janssen-Cilag Ltd.
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants with diagnosis confirmed with Hepatitis C infection being followed into the reference centers * There is no restriction on fibrosis stage or clinical liver disease * There is no restriction for comorbities or coinfections * Diagnosis of chronic HCV infection detected by anti-HCV (ELISA assays), HCV Ribonucleic acid (RNA) (polymerase chain reaction \[PCR\] reaction) with identification of genotype
Exclusion criteria
* Male or female participant with age greater than or equal to 18 years * participating in another interventional clinical trial * Treated participants who achieved sustained Virological Response (SVR)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with chronic hepatitis C infection | Day 1 | Data will be collected through medical records of the participants. |
| Date of last visit | Day 1 | — |
| Number of Participants with chronic hepatitis C infection Reported Based on City and States | Day 1 | Data will be collected through medical records of the participants. |
| Number of Participants with chronic hepatitis C infection Based on precedence | Day 1 | Data will be collected through medical records of the participants. |
| Mean Age of Participants with chronic hepatitis C infection | Day 1 | Data will be collected through medical records of the participants. |
| Number of Males and Females with chronic hepatitis C infection | Day 1 | Data will be collected through medical records of the participants. |
| Number of participants with chronic hepatitis C infection Reported Based on Race | Day 1 | Data will be collected through medical records of the participants. |
| Mode of Hepatitis C virus (HCV) transmission | Day 1 | Data will be collected through medical records of the participants. Mode of HCV transmission route (unsafe injections, hemodialysis, infection drug use, blood transfusion, sexual transmission, vertical transmission, unknown, other) will be analysed by number of participants infected with HCV per transmission route. |
| Duration of diagnosis of chronic hepatitis C infection | Day 1 | Data will be collected through medical records of the participants. |
| HCV genotype and subtype | Day 1 | Data will be collected through medical records of the participants. |
| Liver characteristics: Number of Participants with extra hepatic manifestations | Day 1 | Data will be collected through medical records of the participants. Presence or absence of extra hepatic manifestations (cryoglobulinemia, lymphoma, Sjogren syndrome, glomerulopathy, Porphyria cutanea tarda, liquen planus, diabetes mellitus, thyroiditis, arthralgia). |
| Liver characteristics: Number of Participants with presence of comorbidities | Day 1 | Data will be collected through medical records of the participants. Presence of comorbidities (amount of alcohol ingestion, metabolic syndrome, hepatocellular carcinoma, organ transplantation, diabetes, immunodeficiency, renal insufficiency and dialysis, use of drugs) will be collected. |
| Liver characteristics: Model for End-Stage Liver Disease (MELD) Score and Child Pugh score | Day 1 | MELD is a scoring system for assessing the severity of chronic liver disease. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). |
| Liver characteristics: Number of Participants with Fibrosis based on Fibroscan | Day 1 | Data will be collected through medical records of the participants. |
| Number of Participants with Coinfections | Day 1 | Data will be collected through medical records of the participants. |
| HCV treatment status on Day 1: Percentage of participants receiving antiviral treatment | Day 1 | Data will be collected through medical records of the participants. |
| HCV treatment status on Day 1: Causes of interruption in treatment | Day 1 | Data will be collected through medical records of the participants. Causes of interruption to antiviral therapy will be collected and reported. |
| HCV treatment status on Day 1: Number of participants treated without Sustained Virological Response (SVR) | Day 1 | Data will be collected through medical records of the participants. |
| Treatment regimen | Day 1 | The drugs used and time of treatment will be collected through medical records of the participants. |
| Number of participants with Adverse Events (AEs) | Day 1 | — |
Countries
Brazil
Outcome results
None listed